Anemia following zinc treatment for Wilson’s disease: a case report and literature review

Cai, Sha; Gong, Jing‐Yu; Yang, Jianqi; Wang, Jian‐She

doi:10.1186/s12876-019-1038-5

Cited by 9 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, rare cases of gastrointestinal reactions and hepatic deterioration can occur during zinc therapy [83][84][85]. Up to now, eight patients with anemia after a long period of zinc therapy for WD have been reported [86], thus regular follow-up during zinc treatment and the involvement of specialists in the long-term management of Wilson's disease are recommended.…”

Section: Zinc In the Therapy Of Wilson's Diseasementioning

confidence: 99%

Zinc as a Drug for Wilson’s Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury

et al. 2021

View full text Add to dashboard Cite

Zinc is the second most abundant trace element in the human body, and it plays a fundamental role in human physiology, being an integral component of hundreds of enzymes and transcription factors. The discovery that zinc atoms may compete with copper for their absorption in the gastrointestinal tract let to introduce zinc in the therapy of Wilson’s disease, a congenital disorder of copper metabolism characterized by a systemic copper storage. Nowadays, zinc salts are considered one of the best therapeutic approach in patients affected by Wilson’s disease. On the basis of the similarities, at histological level, between Wilson’s disease and non-alcoholic liver disease, zinc has been successfully introduced in the therapy of non-alcoholic liver disease, with positive effects both on insulin resistance and oxidative stress. Recently, zinc deficiency has been indicated as a possible factor responsible for the susceptibility of elderly patients to undergo infection by SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. Here, we present the data correlating zinc deficiency with the insurgence and progression of Covid-19 with low zinc levels associated with severe disease states. Finally, the relevance of zinc supplementation in aged people at risk for SARS-CoV-2 is underlined, with the aim that the zinc-based drug, classically used in the treatment of copper overload, might be recorded as one of the tools reducing the mortality of COVID-19, particularly in elderly people.

show abstract

Section: Zinc In the Therapy Of Wilson's Diseasementioning

confidence: 99%

Zinc as a Drug for Wilson’s Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Hypocupremia with zinc preparations has also been reported in Wilson's disease, a copper overload disorder. (28) Poor prognosis has also been reported in cases where serum zinc has not improved after zinc supplementa-tion. (26) Although zinc has been studied for many years, there is still a lack of evidence about effective ways to improve zinc deficiency.…”

Section: Discussionmentioning

confidence: 99%

Zinc supplementation with polaprezinc was associated with improvements in albumin, prothrombin time activity, and hemoglobin in ‍chronic liver disease

Abiru,

Kugiyama,

Suehiro

et al. 2024

J. Clin. Biochem. Nutr.

View full text Add to dashboard Cite

Zinc deficiency occurs in a variety of diseases, including chronic liver disease (CLD). We investigated the correlation between zinc levels and biochemical and hematological tests in CLD and the effect of zinc supplementation with polaprezinc on these values. The first study (Study 1) was a retrospective observational study of 490 patients with CLD not receiving zinc supplementation, with data available from September 2009 to August 2021. Univariate and multiple regression analysis showed that serum zinc levels correlated most strongly with albumin (Alb) and also significantly with prothrombin time activity (PT%) and hemoglobin (Hb). A subsequent study (Study 2) focused on patients with advanced CLD who used polaprezinc for more than 90 days between January 2005 and August 2021. Using a self-controlled design with the 6-month period prior to polaprezinc as the control period, comparisons showed that Alb ( p <0.0001), PT% ( p <0.0005), and Hb ( p <0.01) were significantly improved in the polaprezinc-treated patients compared to the control group. In conclusion, serum zinc levels were correlated with serum Alb, Hb, and PT% in patients with CLD, and zinc supplementation with polaprezinc was associated with improvements in Alb, Hb, and PT% within at least 6 months.

show abstract

“…An interaction between metals, such as zinc/ copper and zinc/ iron, has been widely reported in the past. In the case of copper for example, there are several reports in the clinical literature where zinc supplementation in coeliac disease, sickle cell anemia, acrodermatitis enteropathica and Wilson's disease results (potentially via an effect on proteins such as metallothionein) in severe copper deficiency [34][35][36][37]. Similarly, a study in Caco-2 cells demonstrated that there is an inverse relationship between zinc and iron such that increased levels of extracellular zinc applied to the cells results in decreasing intracellular iron levels [38].…”

Section: Discussionmentioning

confidence: 99%

Zinc Transporter-3 Knockout Mice Demonstrate Age-Dependent Alterations in the Metalloproteome

Hancock

Portbury

Gunn

et al. 2020

IJMS

View full text Add to dashboard Cite

Metals are critical cellular elements that are involved in a variety of cellular processes, with recent literature demonstrating that zinc, and the synaptic zinc transporter (ZnT3), are specifically involved in learning and memory and may also be key players in age-related neurodegenerative disorders such as Alzheimer’s disease. Whilst the cellular content and location of metals is critical, recent data has demonstrated that the metalation state of proteins is a determinant of protein function and potential toxicity. As we have previously reported that ZnT3 knockout (KO) mice have deficits in total zinc levels at both 3 and 6 months of age, we were interested in whether there might be changes in the metalloproteomic profile in these animals. To do this, we utilised size exclusion chromatography-inductively coupled plasma mass spectrometry (SEC-ICP-MS) and examined hippocampal homogenates from ZnT3 KO and age-matched wild-type mice at 3, 6 and 18 months of age. Our data suggest that there are alterations in specific metal binding proteins, for zinc, copper and iron all being modulated in the ZnT3 KO mice compared to wild-type (WT). These data suggest that ZnT3 KO mice may have impairments in the levels or localisation of multiple transition metals, and that copper- and iron-dependent cellular pathways may also be impacted in these mice.

show abstract

Anemia following zinc treatment for Wilson’s disease: a case report and literature review

Cited by 9 publications

References 34 publications

Zinc as a Drug for Wilson’s Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury

Zinc as a Drug for Wilson’s Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury

Zinc supplementation with polaprezinc was associated with improvements in albumin, prothrombin time activity, and hemoglobin in ‍chronic liver disease

Zinc Transporter-3 Knockout Mice Demonstrate Age-Dependent Alterations in the Metalloproteome

Contact Info

Product

Resources

About